- Bod Science (BOD) pens letter of intent with Antah Group to commercialise medicinal cannabis products in Malaysia
- The companies plan to identify states which are expected to benefit from medical cannabis therapy, including anxiety disorders and major depressive disorder
- There have been no previous clinical trials or opportunities to explore the impact of cannabis in the Malaysia’s health system to date
- Once the trials are complete, Antah will have exclusive use of Bod’s product for sales and distribution
- Shares dips 2.04 per cent to 4.8 cents at 11:50am AEST
Bod Science (BOD) has penned a letter of intent with Antah Group to develop and commercialise medicinal cannabis products in Malaysia.
Through clinical trials, the two company’s aim to introduce and register medicinal cannabis in Malaysian health care.
Once the trials are complete, Antah will have exclusive use of Bod’s product for sales and distribution.
The companies plan to identify states which are expected to benefit from medical cannabis therapy, including anxiety disorders and major depressive disorder.
In Malaysia, there have been no clinical trials or opportunities to explore the impact of Cannabis in the country’s health system to date.
Antah is one of the largest investment holding companies in Malaysia holding diverse interests in sectors such as health care, power generation, and property development.
The agreement sets out the framework on how the company’s plan to collaborate with specific formal agreements to follow.
Some of the key obligations include Bod supplying the medical cannabis to be used in the agreed clinical trial. With the costs set to be reimbursed at an agreed price, Bod will supply the drug to Antah for commercial distribution once the trial is completed.
Antah will also have exclusive rights to the medical cannabis products in Malaysia, including rights to sell and distribute Bod’s products.
“The collaboration enables Bod with a value-driving opportunity to be at the forefront of exploration into the use of medical cannabis in the Malaysian healthcare industry alongside one of the country’s largest companies,” Bod CEO Jo Patterson said.
BOD slumped 2.04 per cent to 4.8 cents at 11:50am AEST.